Oncolix 10-K 14 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 14, 2018	Jun. 30, 2017
Document and Entity Information:
Entity Central Index Key	1,584,137
Entity Registrant Name	Oncolix, Inc.
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Trading Symbol	oncx
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Public Float			$ 5,241,374
Entity Common Stock, Shares Outstanding		104,477,936
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 494,410	$ 15,264
Prepaid services with related parties	313,777	363,089
Prepaid expenses	81,210	3,802
Total current assets	889,397	382,155
Property and equipment, net
Deferred offering costs		38,687
Total assets	889,397	420,842
Current liabilities
Accounts payable and accrued expenses	43,035	643,473
Related party payable and accrued expenses	261,157	375,217
Convertible notes and accrued interest payable	897,111	198,547
Accounts payable to Greenville Health System and affiliates	61,935	61,935
Total current liabilities	1,263,238	1,279,172
Deferred compensation	1,268,013	1,268,013
Total liabilities	2,531,251	2,547,185
Commitments and contingencies
Stockholders' deficit
Common stock, $0.0001 par value; 950,000,000 shares authorized, 104,477,936 and 71,153,300 shares issued and outstanding at December 31, 2017 and 2016, respectively	10,448	7,115
Additional paid-in capital	20,960,237	16,840,328
Accumulated deficit	(22,618,843)	(18,980,000)
Total Stockholders' deficit	(1,641,854)	(2,126,343)
Total liabilities and stockholders' deficit	889,397	420,842
Series A Preferred Stock [Member]
Stockholders' deficit
Series A preferred stock, $0.001 par value, 150,000,000 shares authorized, 63,038,284 and 62,138,680 shares issued and outstanding at December 31, 2017 and 2016, respectively	$ 6,304	$ 6,214

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Stockholders' deficit
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	950,000,000	950,000,000
Common Stock, Shares Issued	104,477,936	71,153,300
Common Stock, Shares Outstanding	104,477,936	71,153,300
Preferred Sock, Shares Authorized	250,000,000
Series A Preferred Stock [Member]
Stockholders' deficit
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Sock, Shares Authorized	150,000,000	150,000,000
Peferred Stock, Shares Issued	63,038,284	62,138,680
Preferred Stock, Shares Outstanding	63,038,284	62,138,680

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Consolidated Statements Of Operations
Revenues
Expenses
Research and development expenses	462,632	709,009
General and administrative expenses	1,489,941	620,835
Total operating expenses	1,952,573	1,329,844
Gain on extenguishment of debt	(437,184)
Interest expense on convertible notes	1,841,365	55,912
Net loss	$ (3,356,754)	$ (1,385,756)
Loss per common share - basic and diluted	$ (0.040)	$ (0.019)
Weighted average common shares outstanding - basic and diluted	84,781,491	71,148,163

Consolidated Statements of Stoc

Consolidated Statements of Stockholders Deficit - USD ($)	Common Stock	Series A Preferred Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, Shares at Dec. 31, 2015	71,133,300	62,119,080
Beginning balance, Amount at Dec. 31, 2015	$ 7,113	$ 6,212	$ 16,757,809	$ (17,594,244)	$ (823,110)
Sale of series A preferred stock and warrants for cash, Shares		19,600
Sale of series A preferred stock and warrants for cash, Amount		$ 2	1,468		1,470
Warrants issued with indebtedness			41,366		41,366
Warrant issued to placement agent			38,687		38,687
Exercise of stock option for cash, Shares	20,000
Exercise of stock option for cash, Amount	$ 2		998		1,000
Warrant issued for services
Beneficial conversion feature of debt issued
Net loss				(1,385,756)	(1,385,756)
Ending balance, Shares at Dec. 31, 2016	71,153,300	62,138,680
Ending balance, Amount at Dec. 31, 2016	$ 7,115	$ 6,214	16,840,328	(18,980,000)	(2,126,343)
Warrants issued with indebtedness			1,658,905		1,658,905
Warrant issued to placement agent			267,422		267,422
Exercise of stock option for cash, Shares	200,000
Exercise of stock option for cash, Amount	$ 20		980		1,000
Acquisition of AEPP, Shares	31,765,903
Acquisition of AEPP, Amount	$ 3,177		(3,177)
Warrant issued for services			4,862		4,862
Beneficial conversion feature of debt issued			1,822,248		1,822,248
Payment of accrued interest with Common Stock, Shares	625,400
Payment of accrued interest with Common Stock, Amount	$ 63		46,863		46,926
Common Stock issued for services, Shares	733,333
Common Stock issued for services, Amount	$ 73		39,807		39,880
Cashless exercise of warrants, Shares		899,604
Cashless exercise of warrants, Amount		$ 90	(90)
Imputed dividend for adjustment of Series A conversion price into Common Stock			282,089	(282,089)
Net loss				(3,356,754)	(3,356,754)
Ending balance, Shares at Dec. 31, 2017	104,477,936	63,038,284
Ending balance, Amount at Dec. 31, 2017	$ 10,448	$ 6,304	$ 20,960,237	$ (22,618,843)	$ (1,641,854)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (3,356,754)	$ (1,385,756)
Adjustments to reconcile net loss to net cash used in operating activities
Warrant issued for services	4,862
Accretion of discount on notes payable	1,579,807	50,749
Gain on extinguishment of debt	(437,184)
Changes in operating assets and liabilities:
Prepaid and other current assets	10,591	130,001
Related party accounts payable and accrued expenses	(114,060)	591,512
Accounts payable and accrued expenses	(68,696)	168,225
Accounts payable to Greenville Health System and affiliates
Net cash used in operating activities	(2,381,434)	(445,269)
Cash flows from financing activities
Proceeds from exercise of stock options	1,000	1,000
Proceeds from sale of convertible notes and warrants	2,979,580	184,000
Payment of secured notes	(120,000)
Proceeds from sale of Series A preferred stock and warrants		1,470
Net cash provided by financing activities	2,860,580	186,470
Net increase (decrease) in cash and cash equivalents	479,146	(258,799)
Cash and cash equivalents at beginning of period	15,264	274,063
Cash and cash equivalents at end of period	494,410	15,264
Non-cash financing activities
Stock issued to pay interest and other liabilities	86,806
Stock issued on cashless exercise of warrants	90
Beneficial conversion feature of notes issued	1,822,248
Stock assumed in reverse merger	3,177
Warrants issued in debt modifications	19,900
Warrants issued to placement agent	267,422	38,687
Debt discount related to warrants issued	1,639,005	41,366
Imputed dividend for adjustment of series A conversion price into common stock	282,089
Supplemental information
Interest paid in cash	$ 117,010

Background and Basis of Present

Background and Basis of Presentation	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 1. Background and Basis of Presentation	On April 8, 2017, Oncolix, Inc., a private Delaware corporation (“Oncolix/DE”) acquired approximately 66% of the outstanding common stock of Advanced Environmental Petroleum Producers, Inc., a Florida corporation (“AEPP”), a public entity traded on the over-the-counter market with limited or no operating activities and no indebtedness. Oncolix paid $315,000 in cash and paid a fee to an investment banker of $50,000 in connection with this transaction. On August 3, 2017, pursuant to a reverse merger, AEPP acquired all of the outstanding equity interest of Oncolix/DE and assumed responsibility for the issuance of equity securities under Oncolix/DE’s options, warrants and convertible debt (the “Merger”) as described further herein. The Merger was treated as a reverse acquisition of AEPP for financial accounting and reporting purposes. As such, Oncolix/DE was treated as the acquirer and AEPP was treated as the acquired entity for accounting and financial reporting purposes. Accordingly, the financial statements of AEPP for all periods prior to August 3, 2017 are those of Oncolix/DE. Because of the acquisition of a controlling interest on April 8, 2017, the financial statements of AEPP are consolidated with Oncolix/DE since April 2017. The $365,000 purchase price for stock of AEPP by Oncolix/DE is treated as an expense of the merger, and the shares of AEPP Common Stock not owned by Oncolix/DE are treated as shares outstanding subsequent to April 2017. AEPP’s assets, liabilities and results of operations for periods after April 2017 are the consolidated assets, liabilities and results of operations of AEPP and Oncolix/DE. In the Merger, each stockholder of Oncolix/DE received 20 shares of a substantially identical class of AEPP stock (Common or Series A Preferred, each with a par value of $0.0001) in exchange for each share of Oncolix/DE (par value $0.001). In addition, each option or warrant became exercisable for 20 shares of the identical class of AEPP stock for each share of Oncolix/DE, and the exercise price was adjusted by dividing the price per Oncolix/DE share by 20. The shares of AEPP Common Stock owned by Oncolix/DE were cancelled in the Merger. After the Merger, AEPP had 103,536,103 shares of Common Stock, $0.0001 par value, issued and outstanding, of which 71,778,700 shares were issued to the former stockholders of Oncolix/DE. In addition, AEPP had 62,138,680 shares of Series A Preferred Stock, $0.0001, issued and outstanding, all of which were owned by the former stockholders of Oncolix/DE. The financial statements for all periods have been adjusted to reflect the adjusted number of shares resulting from the exchange ratio in the Merger (the 20:1 exchange ratio), effectively a stock split for accounting purposes, and the adjustment of the par value to $0.0001. Contemporaneously with the Merger, Oncolix issued a series of short-term senior secured convertible notes (the “August Notes”) and related warrants to acquire Common Stock (i) in exchange for prior indebtedness of Oncolix/DE and (ii) for cash proceeds of $2 million. See Note 5. On September 27, 2017, AEPP filed an amendment with the Florida Secretary of State and changed its name to Oncolix, Inc. As used in these consolidated financial statements, “We”, “Us”, “Our”, “Oncolix” or the “Company” refers to Oncolix/DE prior to April 2017 and the consolidated Oncolix and Oncolix/DE subsequent to such date. Description of business We are developing medical therapies for the treatment of cancer. The Company’s activities are focused on the development of Prolanta™ for the treatment of gynecological cancers. Oncolix is incorporated in Florida, and we commenced operations on January 24, 2007. At the commencement of our operations, certain intellectual property was transferred to us by a subsidiary of Greenville Health Corporation (collectively, “GHC”), a component unit of Greenville Health System (“GHS”) of South Carolina. Prior to the Merger in August 2017, GHC was the majority stockholder of Oncolix. See Notes 3, 7 and 8. As a clinical-stage biotechnology company, we have no revenues and must raise substantial additional capital to support the completion of our development and commercialization activities. The Company’s business is subject to significant risks and uncertainties, including the risk of failure to secure additional funding for the Company’s future operations and to repay its existing indebtedness. . Going concern We have experienced negative cash flows from operations since the commencement of operations, and we expect these losses to continue into the foreseeable future as we continue the development and clinical testing of our principal product candidate, Prolanta™, and seek regulatory approval to market products. In August 2017, we completed a debt financing through the issuance of the August Notes which are expected to fund our operations into April 2018. See Note 5. The August Notes mature in seven installments during 2018. We are currently seeking financing that would fund repayment of this debt and fund operations through at least 2019. Accordingly, our continued operations are dependent on our ability to raise additional capital through the sale of equity or debt securities or through the licensing of our products. In the event we are unable to raise sufficient funds, we would have to substantially alter, or possibly even discontinue or curtail operations, or sell assets at distressed prices. This uncertainty raises substantial doubt about our ability to continue as a going concern, as noted in the opinion of our independent registered public accounting firm in the audited financial statements as of December 31, 2017. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 2. Summary of Significant Accounting Policies	Use of estimates To prepare our financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”), we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made regarding the realization of deferred tax assets, the calculation of the fair value of stock options awarded, the estimation of the value of warrants issued in conjunction with capital stock or for services, and the projected realization of the carrying basis of our assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. Cash and cash equivalents Our cash balances are not restricted from use and we have no investments or marketable securities during the periods reported. Marketable securities with maturities of three months or less are considered to be cash equivalents. Research and development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits of employees engaged in research; the cost of consultants engaged in our research activities; the cost of developing methods to manufacture our investigational drug products; the costs of production of investigation drugs for use in research, animal and human testing; the costs of the testing of our products in animal models and in human testing; the cost of research conducted on our behalf at academic institutions; the depreciation of equipment used in research; the cost of obtaining patents for the protection of our intellectual property; and other costs associated with these activities. These costs are accounted for in accordance with Accounting Standards Codification (“ASC”) subtopic 730-10, “Research and Development,” which requires all research and development costs to be charged to expense as incurred. Our agreements with both the manufacturer of our drug Prolanta and the organizations that will provide monitoring and regulatory services for our clinical trials provide that our capital stock was issued for part of the value of the total services rendered. The original value of the stock issued was recorded as a prepayment of future services and is expensed as the services are rendered. The remaining balance is reflected as prepaid services in the accompanying balance sheets. Property and equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of five years for laboratory equipment and three years for office furniture and equipment. As of December 31, 2017 and 2016, property and equipment was fully depreciated, and there was no depreciation expense recorded in either year. Intangible assets The costs of obtaining patent protection for our intellectual property are expensed as incurred given the uncertainty of successful development, ultimate regulatory approval and commercialization of products developed using this technology. Deferred offering costs Oncolix defers legal and certain other costs related to financing activities until the completion or termination of the offering. If the financing to which such costs are related is terminated, such costs are expensed. If the costs are related to a debt financing, the costs are amortized as additional interest expense over the period prior to maturity. Concentrations of risk We have engaged a contract manufacturer to develop methods of production of Prolanta and to produce quantities necessary for our animal and human testing. Accordingly, our operations are dependent upon the manufacturer’s ability to manufacture suitable quantities of Prolanta in compliance with regulatory requirements and within acceptable timeframes, and to maintain regulatory licenses for its operations. Failure to maintain such regulatory requirements would have a material impact on our operations. We incurred contract manufacturing costs to this manufacturer of $58,153 and $305,098 during the years ended December 31, 2017 and 2016, respectively. Financial instruments Our financial instruments consist of cash and cash equivalents, accounts payable and notes payable. We believe that the carrying amounts of the financial instruments classified as current assets and liabilities approximate their fair values because of their short-term nature. As discussed in Note 5, certain of our notes payable have a conversion feature at a discount to future equity offerings. We evaluate the carrying value of these notes payable at the closing of any offering to determine if an adjustment is appropriate. As of December 31, 2017, no adjustments were required. Income taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in our ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be limitations on the amount of net loss and credit carry forwards that could be used to offset future taxable income. We believe the reverse merger on August 3, 2017, will restrict the use of accumulated tax attributes prior to such date, but this is not expected to affect our federal tax liability for the foreseeable future because of expected future tax losses given the early stage of development of Prolanta. In addition, a transfer of our capital stock held by GHC among its affiliated companies provided additional restrictions on the utilization of tax attributes. We will recognize the impact of an uncertain tax position only if that position is more likely than not of being sustained upon examination by the taxing authority based on the technical merits of the position. We will account for interest and penalties relating to an uncertain tax position in the current period statement of operations, as necessary. During December 2017, the US enacted the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”), which substantially reduced the federal tax rate for US corporations. The 2017 Tax Act also reduced the benefits available from the Orphan Drug Tax Credit. We previously have recorded a valuation allowance to fully offset our deferred tax assets, and this valuation allowance was adjusted during 2017 to offset the changes in deferred tax assets related to the 2017 Tax Act. Accordingly, the 2017 Tax Act did not have an effect on our results of operations or financial position. Stock-based compensation We maintained an equity compensation plan under which incentive stock options and non-qualified stock options were granted to employees, independent members of our Board of Directors and outside consultants. The right to make grants under this plan expired on December 31, 2016, and we expect a new plan will be adopted in 2018. During 2017, we issued a warrant as part of the compensation to a new director of the Company. See Note 3. We recognize stock-based compensation in accordance with ASC topic 718, “Compensation”, for options and warrants granted as compensation. Deferred compensation The officers of the Company have voluntarily deferred the payment of certain compensation in varying amounts from 2012 through 2016, and the amounts of such deferral have varied with the financial resources available to Oncolix. During 2015, these officers agreed that the deferred compensation would be paid only from the proceeds of future equity offerings after 2017 or from the sale of assets, and not be paid using the existing current assets of the Company. Accordingly, the cumulative unpaid compensation is included in the accompanying condensed balance sheets as a non-current liability, deferred compensation. As of December 31, 2017 and 2016, $1,268,013 is reflected as deferred compensation in the accompanying condensed balance sheets. Rent expense We lease administrative offices in Houston, Texas under a lease which expires on March 31, 2019. Rent expense for the years ended December 31, 2017 and 2016 was $42,149 and $42,083, respectively. The remaining rental obligation under the lease is $40,680 in 2018 and $10,248 in 2019. Recent accounting standards On February 25, 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases. ASU No. 2016-02 requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet for all leases of property, plant and equipment with lease terms greater than 12 months. Prior to this accounting standard, only capital leases were recognized on the balance sheet. ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. This ASU must be applied using a retrospective approach upon adoption. The Company believes this ASU will not have a significant effect on its financial statements. During July 2017, the FASB issued ASU 2017-11, which addresses certain provisions regarding the determination of whether financial instruments are derivatives. Early adoption by the Company was permitted, and retrospective treatment was required. There was no retrospective effect related to the Company’s early adoption, but the accounting treatment of the notes and warrants issued in August 2017 as well as the company’s Series A Preferred Stock was affected. See Notes 3 and 5.

Capital Stock, Options and Warr

Capital Stock, Options and Warrants	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 3. Capital Stock, Options and Warrants	We have 950,000,000 authorized shares of Common Stock, $0.0001 par value, and 250,000,000 authorized shares of preferred stock, of which 150,000,000 are designated as Series A Preferred Stock, $0.0001 par value. As of December 31, 2017, 104,477,936 shares of Common Stock were issued and outstanding, 63,038,284 shares of Series A Preferred Stock, convertible into 66,871,012 shares of Common Stock, were issued and outstanding. The shares of Common Stock include the 31,765,903 shares held by the remaining shareholders of Oncolix prior to our acquisition of control on April 8, 2017. In addition, as of December 31, 2017, we have outstanding options to acquire up to 6,800,000 shares of Common Stock, warrants to acquire up to 49,477,380 shares of Series A Preferred Stock and warrants to acquire up to 65,560,120 shares of Common Stock. We may issue an additional 76,889,231 shares of Common Stock if holders of secured notes voluntarily convert. If fully exercised and converted into Common Stock, there would be 373,083,905 shares of Common Stock outstanding. In addition, we may be obligated to issue an additional 14,000,000 shares of Series A Preferred Stock in exchange for future clinical research services. Series A Preferred Stock Each share of Series A Preferred Stock is currently convertible into 1.0608 shares of Common Stock. This conversion ratio is subject to adjustment for certain dilutive events. If a liquidation event occurs, each share of Series A Preferred Stock is entitled to a liquidation preference of $0.075 per share, and then each share will receive distributions ratably with the Common Stock based on the then-existing conversion ratio. As of December 31, 2017, the liquidation preference of the outstanding shares of Series A Preferred Stock is $4,727,871. The holders of Series A Preferred Stock have voting rights with the Common Stock based on the then-existing conversion ratio, and also have certain separate voting rights for certain matters. As long as at least 14,000,000 shares of Series A Preferred Stock are outstanding, the holders of the Series A Preferred Stock have certain protective rights to nominate a director to the Board of Directors, who shall have the right to approve certain transactions. In addition, as long as at least 14,000,000 shares of Series A Preferred Stock are outstanding, the holders of the Series A Preferred Stock have the right to vote separately as a class to approve certain amendments to the certificate of incorporation, any liquidation event, and certain issuances of capital stock. During 2017, as a result of the change in the conversion price of the August Notes from $0.075 to $0.0545, the conversion price of the Series A Preferred Stock was adjusted from $0.075 to $0.0707. Accordingly, as of December 31, 2017, the shares of Series A Preferred Stock may be converted into Common Stock at any time at the ratio of 1.0608 shares of Common Stock for every share of Series A Preferred Stock. For accounting purposes this adjustment in conversion price was treated as a dividend to the Series A holders equal to the value of the additional shares of Common Stock issuable upon conversion, or $282,089. The Series A Preferred Stock will automatically convert upon either the written consent of the holders of the majority of such shares or the closing of a firm-commitment underwritten public offering with gross proceeds of at least $10 million. GHC liquidation rights On January 24, 2007, the Company issued 24,000,000 shares of Common Stock to GHC in exchange for certain intellectual property and a commitment by GHC to invest $3.0 million to fund the Company’s operations. GHC retains the rights to the contributed intellectual property in the event of a bankruptcy or liquidation of the Company. GHC has subordinated these rights in connection with the Company’s borrowings. Contract manufacturing arrangements and payment in equity During August 2009, we engaged a non-US manufacturer for the production of Prolanta™ and to provide certain quality assurance services. Our agreement ended in August 2016. Of amounts earned by the manufacturer, approximately 58%, or $1.5 million, was payable in Oncolix Common Stock at $0.15 per share, and we issued 10,000,000 shares of Common Stock to the manufacturer. The remaining amounts due under the contract were payable in cash. As of December 31, 2016, we deducted the balance of the prepayment of $120,688 from the amounts owed to the contract manufacturer. Such amounts have been reclassified to prepaid services at December 31, 2017 because the current amounts due to the contract manufacturer were incurred outside of the previous contract. Clinical research arrangements and payment in equity During August 2011, we agreed to pay 10% of the cost of services rendered by a non-US based clinical research organization through the issuance of 333,340 shares of Common Stock at $0.15 per share. The $50,000 value of the Common Stock was recorded as a prepayment of future services. As of December 31, 2017 and 2016, the unearned portion of the value of the equity issued, $43,090, is reflected as prepaid services in the accompanying condensed balance sheets. During January 2015, as part of a financing transaction described below, we agreed to pay the cost of services by a US-based clinical research organization through the issuance of Series A Preferred Stock and warrants to acquire Series A Preferred Stock. The $450,000 value of the initial issuance of Series A Preferred Stock was recorded as a prepayment of future services. As of December 31, 2017 and 2016, respectively, the unearned portion of the value of the equity issued reflected as a prepayment in the accompanying condensed balance sheets was $150,000 and $269,999, respectively. Additionally, the clinical research organization may perform an additional $1,050,000 in services and receive an additional 14,000,000 shares of Series A Preferred Stock. Texas Emerging Technology Fund Investment The Texas Emerging Technology Fund (“TETF”), an economic development affiliate of the State of Texas, is the majority holder of the Company’s Series A Preferred Stock as of December 31, 2017 and 2016. We agreed to certain conditions related to the TETF investment, including certain representations and warranties. Our obligations to TETF generally expire on September 30, 2020. In the event that we do not maintain our principal place of business or principal executive offices in Texas, TETF may require us to repay the $3.9 million investment plus eight percent interest per annum, compounded annually, from the date of the investment, essentially as a stipulated damage or penalty, and TETF will retain its shares of Series A Preferred Stock. In the event of a breach of other conditions of the investment or representations and warranties, TETF may seek any remedies it may have in law or equity. We can terminate our obligations to TETF at any time by the repayment of the amount invested plus 8% interest calculated as described above. Warrants to Acquire Series A Preferred Stock As of December 31, 2017 and 2016, respectively, we have issued warrants to acquire up to 49,477,380 and 50,810,720 shares of Series A Preferred Stock (the “Preferred Warrants”). The Preferred Warrants expire if not otherwise exercised at various dates commencing on January 16, 2020 and ending May 12, 2022. The exercise price is $0.0825 per share, subject to adjustment for certain dilutive transactions. The Preferred Warrants may be exercised on a cash-less basis. During 2016, warrants to acquire 2,666,700 shares of Series A Preferred Stock at $0.0825 per share were issued in connection with a debt financing. See Note 5. During August 2017, one holder exercised on a cashless basis his warrants to acquire 2,333,340 shares and was issued 899,604 shares of Series A Preferred Stock. In connection with the planned sale of convertible notes in 2017, we executed an agreement with a placement agent in 2016. The agreement provides that the agent will receive, in addition to other compensation, a warrant to acquire 2,000,000 shares of Series A Preferred Stock at $0.0825 per share. The warrant expires if not exercised in January 2020 and has cashless exercise provisions. The warrant was issued in December 2016, and the estimated value of the warrant, $38,687, was reflected as a deferred offering cost in the accompanying balance sheets as of December 31, 2016. Warrants to Acquire Common Stock As of December 31, 2017 and 2016, respectively, we have issued warrants to acquire up to 65,560,121 and 0 shares of Common Stock. These warrants include (i) warrants to acquire 59,072,837 shares issued in connection with debt (the “August Warrants”), (ii) warrants to acquire 5,587,284 shares issued as compensation to the placement agent of the August Notes, and (iii) a warrant to acquire 900,000 shares issued as compensation to a director (see “Stock Compensation Expense” below). In connection with the issuance of the August Warrants, warrants to acquire 17,608,280 shares previously issued with debt in 2017 were surrendered. The August Warrants expire if not otherwise exercised on or prior to August 3, 2022. The exercise price of August Warrants to acquire 55,872,837 shares is $0.09 per share, and the exercise price of August Warrants to acquire 3,200,000 shares is $0.0825 per share, subject to adjustment for certain dilutive transactions. The August Warrants may be exercised on a cash-less basis and have anti-dilution provisions for issuances below the then-current exercise price. These “down round” protections do not prevent the warrants being linked to our Common Stock under the provisions of ASU 2017-11, and the warrants are settleable only for Common Stock. Accordingly, the warrants are accounted for as equity and not treated as a derivative in the accompanying financial statements. See Note 5. The warrants issued to the placement agent for the August Notes have terms identical to the August Warrants, expire if not otherwise exercised in or prior to August 3, 2022, and are exercisable at $0.09 per share. The warrants issued to a director as compensation are exercisable at $0.09 per share and expire if not otherwise exercised in or prior to November 30, 2022. See “ Stock Compensation Expense” below for the accounting treatment of this warrant. Stock Compensation Expense The authority to make grants under the 2007 Stock Option Plan expired on December 31, 2016, and no further grants may be made. We expect to adopt a new plan in 2018. As of December 31, 2017 and 2016, respectively, options to acquire 6,800,000 and 7,200,000 shares of Common Stock were outstanding. One option to acquire 200,000 shares was forfeited in July 2017, and one option to acquire 200,000 shares was exercised 2017 for $0.005 per share in cash. During 2017, a director of the Company was issued a warrant to acquire 900,000 shares of Common Stock at $0.09 per share. One-third of the shares could be purchased immediately, one-third can be purchased on the first anniversary, and the remainder may be purchased on the second anniversary. The warrant expires if unexercised on November 30, 2022, and will also expire if the director’s term is terminated. The following table lists the options and warrants granted to officers, directors and consultants during the periods indicated. Number of Common Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Life (Years) Balance January 1, 2016 7,820,000 $ 0.0100 5.76 Exercises (20,000 ) $ 0.0500 Forfeitures (600,000 ) $ 0.0150 Balance December 31, 2016 7,200,000 $ 0.0095 4.40 Grants 900,000 $ 0.0900 Exercises (200,000 ) $ 0.0050 Forfeitures (200,000 ) $ 0.0050 Balance December 31, 2017 7,700,000 $ 0.0190 3.64 Vested at December 31, 2017 7,100,000 $ 0.0130 3.53 We recognize stock-based compensation expense for equity awards over the requisite service period of each grant using the Black-Scholes option pricing model to estimate the fair value of the stock options on the date of grant. We do not currently have sufficient historical exercise or forfeiture data on which to base an estimate of the expected term of each option, so we use the life of the grant and assume no forfeitures. Because of the limited trading history of Oncolix Common Stock as a public entity, we use 40% as an estimate of volatility rather than use the historical trading activity of the pre-merger AEPP. We base the risk-free interest rate used in the Black-Scholes option pricing model on the yield currently available in U.S. Treasury securities with comparable maturities. The Company recognized $4,862 in stock compensation expense related to the warrant granted in 2017. As of December 31, 2017, unamortized stock-based compensation expense totaled $9,724.

Loss Per Common Share

Loss Per Common Share	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 4. Loss Per Common Share	Basic loss per Common share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed using the average shares outstanding for the period and applying the treasury stock method to potentially dilutive outstanding options and warrants. In all applicable periods, all potential Common Stock equivalents were anti-dilutive and, accordingly, were not included in the computation of diluted loss per share. These excluded Common Stock equivalents and other potentially dilutive securities during the years ended December 31, 2017 and 2016 included the following: Common-Equivalent Shares as of December 31, 2017 2016 Series A Preferred Stock outstanding, Common equivalent 66,871,012 62,138,160 Warrants to acquire Series A Preferred Stock, Common equivalent 52,485,605 50,810,720 Options to acquire Common Stock 6,800,000 7,200,000 Warrants to acquire Common Stock 65,560,121 - Shares issuable upon conversion of notes 76,889,231 - 268,605,969 120,148,880 See Notes 3 and 5 for the terms of these securities.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 5. Notes Payable	2016 Secured Notes During the second half of 2016, we sold units of a 10% secured note payable (the “2016 Notes”) and a warrant to acquire shares of Series A Preferred Stock. As of December 31, 2016, we issued $200,000 in principal amount of the 2016 Notes and warrants to acquire 2,666,700 shares of Series A Preferred Stock at $0.0825 per share. The original maturities of the 2016 Notes were between March 2017 and May 2017, and the 2016 Notes were secured by the assets of Oncolix. These warrants are exercisable through January 2020, and were assigned a value of $41,365 using a Black-Scholes formula, which was recorded as a discount to the notes. Upon maturity, if the noteholders were not offered an option to convert the notes into a new equity offering by the Company, the noteholder was also entitled to receive an additional 20% of the principal amount of the 2016 Notes. The discount attributable to the value of the warrants, the 20% premium, and an additional discount related to the fees and expenses of the issuance of the 2016 Notes of $16,000 was accreted as additional interest expense over the life of the notes. The 2016 Notes had the right to voluntarily convert into the units sold in 2017, as described in the sections below. As a result, the principal of the 2016 Notes was convertible into Common Stock at the price of $0.075 per Common share. During March 2017, $100,000 of principal amount of the 2016 Notes was exchanged for a new series of notes being sold in 2017 – see the following section. The maturity date of the remaining $100,000 of principal of 2016 Notes was extended through May 12, 2017, in exchange for an increase in the interest rate to 18% and the issuance of a warrant to acquire 500,000 shares of Series A Preferred Stock. The warrant is exercisable at $0.0825 per share and expires if not exercised on or prior to March 14, 2022. The discount attributable to the value of this additional warrant ($8,465) was being accreted as additional interest expense over the extended maturity period of the 2016 Note. In May 2017, the maturity of this note was further extended to July 2017, and we issued a second warrant to acquire 500,000 shares of Series A Preferred Stock. The warrant is exercisable at $0.0825 per share and expires if not exercised on or prior to May 12, 2022. The discount attributable to the value of this additional warrant ($11,435) was being accreted as additional interest expense over the extended maturity period of the 2016 Note. During August 2017, the balance of this debt ($120,000) was paid. Additionally, during August 2017 warrants to acquire 2,333,340 shares were exercised on a cashless basis and the holder was issued 899,604 shares of Series A Preferred Stock. See Note 3. During the years ended December 31, 2017 and 2016, respectively, we recorded $89,222 and $55,912 of interest expense attributable to the 2016 Notes, of which $77,814 and $50,749 was accretion. Sale of Convertible Notes in Early 2017 During the first three months of 2017 we sold units consisting of a convertible promissory note (the “2017 Notes”) and a warrant to acquire shares of Common Stock at $0.0825 per share. The 2017 Notes were secured by the assets of the Company and subordinated to the 2016 Notes. As of August 3, 2017, we had issued units for $1,185,000 in cash and the exchange for 2016 Notes, and we issued 2017 Notes with a principal balance of $1,320,621 and warrants to acquire 17,608,280 shares of Common Stock. We paid fees to the placement agent of $103,500 in cash and were also obligated to issue warrants to acquire 1,580,000 shares of Common Stock. These warrants a were assigned a value of $389,421 using a Black-Scholes formula, and these warrants were exchanged for new warrants in the August debt sale as described below. In addition, we incurred cash expenses of $93,889. The maturity of the 2017 Notes was extended to November 2018. At maturity, if we had not offered the noteholders an option to exchange the 2017 Notes for equity securities in an offering with at least $5 million in gross proceeds, each noteholder would also receive an additional payment equal to 20% of the principal of the 2017 Note. The discount attributable to the value of the warrants, the 20% premium, and an additional discount related to the fees and expenses of the issuance of the notes of $197,389 were being accreted as additional interest expense over the life of the notes. The 2017 Notes could also be converted by each holder into shares of Common Stock at a price of $0.075 per Common Shares. The 2017 Notes and accrued interest were exchangeable at a discount into a new equity offering. Interest of 10% was payable quarterly in arrears, and could be paid in our Common Stock at $0.075 per share. On March 31, 2017, and June 30, 2017, we elected to pay accrued interest as of such date by issuing 177,980 and 447,420 shares of our Common Stock, respectively. Such Common Stock was issued in April 2017 and July 2017, respectively. During August 2017, all of the 2017 Notes and related warrants were exchanged for a new series of units of convertible debt and warrants. See below. During the year ended December 31, 2017, we recorded $646,208 of interest expense attributable to the 2017 Notes, of which $586,810 was accretion. Sale of July Secured Notes During July 2017, we sold an $160,000 in principal of secured notes the (“July Notes”) and warrants to acquire 3,200,000 shares of Common Stock at $0.0825 per share. The July Notes were due in February 2018 and the warrants are exercisable through July 2022. The July Notes were secured by all of the assets of the Company. As noted in the following section, the July 2017 Notes were exchanged in a subsequent debt offering in August 2017. During the year ended December 31, 2017, we recorded $103,914 of interest expense attributable to the 2017 Notes, of which $87,914 was accretion August Notes On August 3, 2017, we (i) exchanged $1,561,894 of the outstanding balance of debt plus accrued interest under the 2017 Notes and the July Notes and amounts payable under a consulting agreement and (ii) received $2,000,000 cash for an aggregated purchase price of $3,561,894 in consideration for the issuance of a new series of secured notes (the “August Notes”) with a stated principal balance of $4,190,463. The August Notes were issued at a 15% discount as noted. In addition, holders of the 2017 Notes exchanged warrants to acquire 17,608,280 shares of Common Stock at $0.0825 per share for new Warrants to acquire Common Stock at $0.09 per share, the August Warrants, as described above. The total warrants issued were 55,872,837 shares. These warrants to acquire Common Stock have a five-year term, cashless exercise provisions and anti-dilution protections. See Note 3. The feature of the August Notes allowing conversion into Common Stock was not bifurcated and treated separately as a derivative in the financial statements. This conversion feature, which includes “down round” protection to the noteholders, is considered linked to our Common Stock under the guidance of ASU 2017-11, which was early-adopted by the Company. This conversion feature is considered settleable only for Common Stock and would be classified as equity if bifurcated from the August Notes. Similarly, the related warrants are also considered linked to our Common Stock under the provisions of ASU 2017-11, and are settleable only for Common Stock. Accordingly, the warrants are not accounted for as a derivative. We incurred cash offering costs of $277,289 in connection with the offering, including $164,800 paid to a placement agent. In addition, the placement agent surrendered its rights to receive warrants in connection with the 2017 Notes, and received warrants to acquire 5,587,284 shares at $0.09 per share. These warrants a were assigned a value of $267,422 using a Black-Scholes formula. The closing Oncolix Common Stock price on the date of issuance was $0.109, and the warrants have a five-year term. Because of the limited trading history of Oncolix Common Stock, we continue to use 40% as an estimate of volatility rather than use the historical trading activity of the pre-merger AEPP. The August Notes bear interest at a rate of 10% per annum, payable quarterly on November 1, 2017, February 1, 2018, and May 1, 2018 and thereafter, on a monthly basis until maturity. The interest is payable in cash or, at the option of the Company, subject to compliance with certain strict volume and price conditions, in fully tradable Common Stock at a 25% discount to the average of the five lowest closing bid prices for the 20 trading days prior to the interest payment date. The final maturity of the August Notes is November 1, 2018, but commencing on May 1, 2018 and on the first day of each month thereafter until maturity, we are required to redeem an amount of the August Notes equal to 1/7th of the original principal amount, plus 10% of such monthly redemption amount as a bonus. The principal payments shall be made in cash or, subject to the satisfaction of with certain strict volume and price conditions, in Common Stock valued at a 25% discount to the average of the five lowest closing bid prices for the 20 trading days prior to the amortization date. The August Notes are convertible at the option of the holders at a conversion price equal to $0.0545 per share. The August Notes contain customary anti-dilution protection, including full-ratchet anti-dilution adjustments in the event of certain dilutive issuances (that adjust both price and share amounts). In the event of a closing of an $8 million financing in connection with a change in listing of the Common Stock to Nasdaq or the NYSE, the August Notes shall be subject to mandatory conversion into Common Stock at a 30% discount to the offering price. We are required to offer to prepay in cash the aggregate principal amount of the August Notes at 120% of the principal amount thereof plus any unpaid accrued interest to the date of repayment, at maturity, on the sale of substantially all of the assets of the Company, upon a change of control, upon a qualified offering, or upon a “fundamental transaction” of the Company (such as a reverse merger); in such an event, the holders shall have the right to convert the August Notes prior to the date of any such prepayment. The August Notes contain standard negative covenants customary for transactions of this type. The events of default are also customary for transactions of this type, including default in timely payment of principal or interest, failure to observe or perform any covenant or agreement in the note agreements, the commencement of bankruptcy or insolvency proceedings, failure to timely deliver conversion shares underlying the August Notes, failure to timely file Securities and Exchange Commission filings, failure to satisfy certain market conditions., and the failure to register the resale of Common Stock issuable upon conversion of the August Notes or issuable upon exercise of the August Warrants. The terms of the August Notes require the Company to undertake to register the resale of the Common Stock issuable upon conversion of the Notes and the exercise of the August Warrants. The Company filed a registration statement for all of such Common Stock, but only the Common Stock for certain holders was allowed by the SEC. Approximately 95,139,042 shares underlying the Notes and Warrants were not registered for resale as of December 31, 2017, based on positions taken by the SEC that such holders could not sell shares in a secondary offering. The agreements with the holders have provisions that assess damages in the event that certain registration dates are not met. As of December 31, 2017, the Company believes no damages have accrued with respect to these unregistered shares. For the benefit of the holders of the Notes, the Company has filed and will continue to file registration statements to seek to register the resale of these shares. While the Company believes no damages have accrued as of December 31, 2017, certain holders of Convertible Notes verbally have asserted that damages do accrue under the agreements. As of December 31, 2017, such amount claimed by the holders equals 18% of the related Notes, or $522,349, and accrued interest at 24% per annum of $6,068. Interest would continue to accrue until paid. This potential liability is not recorded in the accompanying financial statements because the Company believes no damages are due as of December 31, 2017. See Note 8. In addition, the failure to register the underlying Common Stock may be an event of default under the agreements. On the date of issuance, the August Notes were convertible into Common Stock at $0.075 per share (subject to adjustment as noted above, which was established at $0.0545 on November 30, 2017), or at a conversion price below the closing market price of $0.109. This “discount” is considered a beneficial conversion feature for accounting purposes. The allocation of carrying basis between the warrants issued and the notes was determined based on relative valuation. The carrying basis attributable to the warrants to acquire Common Stock is $1,194,934. The discount of the initial conversion price from market related to the beneficial conversion feature of the debt was approximately $1,822,000, and such amount was recorded as a reduction of debt and increase in Additional paid-in capital. After deducting offering costs of $544,711 (including the placement agent warrant), the initial net carrying basis of the August Notes was reduced to zero. The principal due at maturity ($4,190,463) plus the 10% bonus payable is being accreted as additional interest over the life of the notes. During the year ended December 31, 2017, respectively, we recorded $1,001,872 of interest expense attributable to the August Notes, of which $827,270 was accretion. As of December 31, 2017, the carrying basis (excluding accrued interest) is comprised of: As of December 31, 2017 Principal due at maturity, including 10% bonus $ 4,609,509 Unamortized issue costs and discount (3,782,239 ) Carrying amount in the accompanying Balance Sheet $ 827,270

Federal Income Tax

Federal Income Tax	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 6. Federal Income Tax	At December 31, 2017 the Company has net operating loss carryforwards (“NOLs”) of approximately $9.2 million and an Orphan Drug Tax Credit of approximately $567,000 which are available to reduce future Federal income taxes. The future utilization of these carryforwards will be severely restricted by various tax regulations as a result of changes in ownership of the Company. These carryforwards begin to expire in 2027, if not utilized. During December 2017, the US enacted the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”), which substantially reduced the federal tax rate for US corporations from 35% to 21% commencing in 2018. The 2017 Tax Act also reduced the benefits available from the Orphan Drug Tax Credit. We previously have recorded a valuation allowance to fully offset our deferred tax assets, which was determined using the previous statutory federal income tax rate of 35%. As of December 31, 2017, we have utilized the newly enacted statutory federal tax rate of 21%, resulting in a reduction in deferred tax assets of approximately $2.8 million. There is substantial uncertainty regarding the ability to utilize our deferred tax assets, and we have recorded a valuation allowance to offset any potential future tax benefit. Accordingly, the 2017 Tax Act did not have an effect on our results of operations or financial position. The following table sets forth the components of our net deferred tax asset as of December 31, 2017 and 2016. As of December 31, 2017 2016 Deferred tax assets (liabilities): Net operating losses $ 1,926,842 $ 2,946,115 Unamortized R&D expenses 323,540 689,178 Unamortized startup costs 1,276,853 1,737,633 Orphan Drug Credit 567,188 431,238 Other, net 64,744 108,104 Total deferred tax assets 4,159,167 5,912,268 Valuation allowance (4,159,167 ) (5,912,268 ) Net deferred tax asset $ - $ - There is no assurance that sufficient taxable income will be generated in the future to utilize the net operating loss carryforward prior to its expiration. A valuation allowance has been recorded to fully offset the deferred tax assets. For the year ended December 31, 2017, the valuation allowance decreased by approximately $1,753,000, primarily as a result of the change in the statutory federal tax rate to 21% for 2018 and future years. The utilization of our deferred tax assets is restricted when substantial changes in our ownership occur, as defined in Section 382 of the Internal Revenue Code. We believe the Merger on August 3, 2017, will restrict the use of accumulated tax attributes prior to such date, but this is not expected to affect our federal tax liability for the foreseeable future because of our expected future tax losses given the early stage of development of Prolanta. In addition, a transfer of our capital stock held by GHC among its affiliated companies in September 2017, provided additional restrictions on the utilization of tax attributes. Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows: For year ended December 31, 2017 2016 Federal tax benefit rate 35.0 % 35.0 % Permanent differences -19.9 % -6.4 % Valuation allowance -15.1 % -28.6 % Effective income tax benefit (provision) rate 0 % 0 %

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 7. Related-Party Transactions	As of December 31, 2017, an affiliate of GHS holds approximately 40% of the voting interest in Oncolix. An affiliate of GHS is the site for clinical trial activities. Accounts payable to GHS and its affiliates for services were approximately $61,935 at December 31, 2017 and 2016, respectively. We have engaged a contract manufacturer and clinical research firms and certain of the costs incurred have been paid or will be paid through the issuance of capital stock. See Note 3.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
NOTE 8. Commitments and Contingencies	Damage Claims for August Notes The terms of the August Notes require the Company to undertake to register the resale of the Common Stock issuable upon conversion of the Notes and the exercise of the August Warrants. As described in Note 5, certain shares were not registered as of December 31, 2017. the Company believes no damages have accrued with respect to these unregistered shares. For the benefit of the holders of the Notes, the Company has filed and will continue to file registration statements to seek to register the resale of these shares. While the Company believes no damages have accrued as of December 31, 2017, certain holders of Convertible Notes verbally have asserted that damages do accrue under the agreements. As of December 31, 2017, such amount claimed by to the holders equals 18% of the related August Notes, or $522,349, and accrued interest at 24% per annum of $6,068. Interest would continue to accrue until paid. This potential liability is not recorded in the accompanying financial statements because thxxe Company believes no damages are due as of December 31, 2017. However, depending on the timing of future registration statements, future damages may accrue. Licenses We licensed certain manufacturing technology for the production of Prolanta. We continue to evaluate processes and methods of manufacturing, but if we utilize this licensed technology we must pay a royalty of up to 2% of future sales. Incentive compensation for equity sales Prior to the Merger, our Chief Executive Officer received 1% of the gross proceeds from certain sales of equity securities, including services paid through the issuance of stock. Such incentive compensation plan has not yet been adopted by Oncolix. No additional compensation expense was recorded pursuant to these arrangements in 2017 and 2016. Engagement of placement agent In connection with our prior financing activities, we engaged a placement agent which received a fee based on the proceeds received by us and a warrant to acquire our Common Stock. The placement agent will also receive a fee equal to 4% of cash received by Oncolix on the exercise of the Common Warrants issued. See Notes 3 and 5. Contingent obligations to Texas Emerging Technology Fund In connection with the investments by the TETF, we agreed to certain conditions, including certain representations and warranties, and the breach of which may result in penalties payable to TETF. See Note 3. Obligation to GHC Upon Bankruptcy or Liquidation In connection with the contribution of intellectual property upon the formation of the Company, GHC retains the rights to the contributed intellectual property in the event of the bankruptcy or liquidation of Oncolix. GHC has subordinated these rights to the security interests of the Convertible Notes. Severance Arrangements for Officers The Company has entered into employment agreements with its officers that provide for a severance payment of 12 to 18 months of the officer’s salary in the event of termination without cause or under certain other conditions.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies Policies
Use of estimates	To prepare our financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”), we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made regarding the realization of deferred tax assets, the calculation of the fair value of stock options awarded, the estimation of the value of warrants issued in conjunction with capital stock or for services, and the projected realization of the carrying basis of our assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Cash and cash equivalents	Our cash balances are not restricted from use and we have no investments or marketable securities during the periods reported. Marketable securities with maturities of three months or less are considered to be cash equivalents.
Research and development	Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits of employees engaged in research; the cost of consultants engaged in our research activities; the cost of developing methods to manufacture our investigational drug products; the costs of production of investigation drugs for use in research, animal and human testing; the costs of the testing of our products in animal models and in human testing; the cost of research conducted on our behalf at academic institutions; the depreciation of equipment used in research; the cost of obtaining patents for the protection of our intellectual property; and other costs associated with these activities. These costs are accounted for in accordance with Accounting Standards Codification (“ASC”) subtopic 730-10, “Research and Development,” which requires all research and development costs to be charged to expense as incurred. Our agreements with both the manufacturer of our drug Prolanta and the organizations that will provide monitoring and regulatory services for our clinical trials provide that our capital stock was issued for part of the value of the total services rendered. The original value of the stock issued was recorded as a prepayment of future services and is expensed as the services are rendered. The remaining balance is reflected as prepaid services in the accompanying balance sheets.
Property and equipment	Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of five years for laboratory equipment and three years for office furniture and equipment. As of December 31, 2017 and 2016, property and equipment was fully depreciated, and there was no depreciation expense recorded in either year.
Intangible assets	The costs of obtaining patent protection for our intellectual property are expensed as incurred given the uncertainty of successful development, ultimate regulatory approval and commercialization of products developed using this technology.
Deferred offering costs	Oncolix defers legal and certain other costs related to financing activities until the completion or termination of the offering. If the financing to which such costs are related is terminated, such costs are expensed. If the costs are related to a debt financing, the costs are amortized as additional interest expense over the period prior to maturity.
Concentrations of risk	We have engaged a contract manufacturer to develop methods of production of Prolanta and to produce quantities necessary for our animal and human testing. Accordingly, our operations are dependent upon the manufacturer’s ability to manufacture suitable quantities of Prolanta in compliance with regulatory requirements and within acceptable timeframes, and to maintain regulatory licenses for its operations. Failure to maintain such regulatory requirements would have a material impact on our operations. We incurred contract manufacturing costs to this manufacturer of $58,153 and $305,098 during the years ended December 31, 2017 and 2016, respectively.
Financial instruments	Our financial instruments consist of cash and cash equivalents, accounts payable and notes payable. We believe that the carrying amounts of the financial instruments classified as current assets and liabilities approximate their fair values because of their short-term nature. As discussed in Note 5, certain of our notes payable have a conversion feature at a discount to future equity offerings. We evaluate the carrying value of these notes payable at the closing of any offering to determine if an adjustment is appropriate. As of December 31, 2017, no adjustments were required.
Income taxes	We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in our ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be limitations on the amount of net loss and credit carry forwards that could be used to offset future taxable income. We believe the reverse merger on August 3, 2017, will restrict the use of accumulated tax attributes prior to such date, but this is not expected to affect our federal tax liability for the foreseeable future because of expected future tax losses given the early stage of development of Prolanta. In addition, a transfer of our capital stock held by GHC among its affiliated companies provided additional restrictions on the utilization of tax attributes. We will recognize the impact of an uncertain tax position only if that position is more likely than not of being sustained upon examination by the taxing authority based on the technical merits of the position. We will account for interest and penalties relating to an uncertain tax position in the current period statement of operations, as necessary. During December 2017, the US enacted the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”), which substantially reduced the federal tax rate for US corporations. The 2017 Tax Act also reduced the benefits available from the Orphan Drug Tax Credit. We previously have recorded a valuation allowance to fully offset our deferred tax assets, and this valuation allowance was adjusted during 2017 to offset the changes in deferred tax assets related to the 2017 Tax Act. Accordingly, the 2017 Tax Act did not have an effect on our results of operations or financial position.
Stock-based compensation	We maintained an equity compensation plan under which incentive stock options and non-qualified stock options were granted to employees, independent members of our Board of Directors and outside consultants. The right to make grants under this plan expired on December 31, 2016, and we expect a new plan will be adopted in 2018. During 2017, we issued a warrant as part of the compensation to a new director of the Company. See Note 3. We recognize stock-based compensation in accordance with ASC topic 718, “Compensation”, for options and warrants granted as compensation.
Deferred compensation	The officers of the Company have voluntarily deferred the payment of certain compensation in varying amounts from 2012 through 2016, and the amounts of such deferral have varied with the financial resources available to Oncolix. During 2015, these officers agreed that the deferred compensation would be paid only from the proceeds of future equity offerings after 2017 or from the sale of assets, and not be paid using the existing current assets of the Company. Accordingly, the cumulative unpaid compensation is included in the accompanying condensed balance sheets as a non-current liability, deferred compensation. As of December 31, 2017 and 2016, $1,268,013 is reflected as deferred compensation in the accompanying condensed balance sheets.
Rent expense	We lease administrative offices in Houston, Texas under a lease which expires on March 31, 2019. Rent expense for the years ended December 31, 2017 and 2016 was $42,149 and $42,083, respectively. The remaining rental obligation under the lease is $40,680 in 2018 and $10,248 in 2019.
Recent accounting standards	On February 25, 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases. ASU No. 2016-02 requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet for all leases of property, plant and equipment with lease terms greater than 12 months. Prior to this accounting standard, only capital leases were recognized on the balance sheet. ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. This ASU must be applied using a retrospective approach upon adoption. The Company believes this ASU will not have a significant effect on its financial statements. During July 2017, the FASB issued ASU 2017-11, which addresses certain provisions regarding the determination of whether financial instruments are derivatives. Early adoption by the Company was permitted, and retrospective treatment was required. There was no retrospective effect related to the Company’s early adoption, but the accounting treatment of the notes and warrants issued in August 2017 as well as the company’s Series A Preferred Stock was affected. See Notes 3 and 5.

Capital Stock, Options and Wa16

Capital Stock, Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Capital Stock Options And Warrants Tables
Schedule of option and warrant	Number of Common Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Life (Years) Balance January 1, 2016 7,820,000 $ 0.0100 5.76 Exercises (20,000 ) $ 0.0500 Forfeitures (600,000 ) $ 0.0150 Balance December 31, 2016 7,200,000 $ 0.0095 4.40 Grants 900,000 $ 0.0900 Exercises (200,000 ) $ 0.0050 Forfeitures (200,000 ) $ 0.0050 Balance December 31, 2017 7,700,000 $ 0.0190 3.64 Vested at December 31, 2017 7,100,000 $ 0.0130 3.53

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2017
Loss Per Common Share Tables
Common Stock equivalents and other potentially dilutive securities	Common-Equivalent Shares as of December 31, 2017 2016 Series A Preferred Stock outstanding, Common equivalent 66,871,012 62,138,160 Warrants to acquire Series A Preferred Stock, Common equivalent 52,485,605 50,810,720 Options to acquire Common Stock 6,800,000 7,200,000 Warrants to acquire Common Stock 65,560,121 - Shares issuable upon conversion of notes 76,889,231 - 268,605,969 120,148,880

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Payable Tables
Notes Payable	As of December 31, 2017 Principal due at maturity, including 10% bonus $ 4,609,509 Unamortized issue costs and discount (3,782,239 ) Carrying amount in the accompanying Balance Sheet $ 827,270

Federal Income Tax (Tables)

Federal Income Tax (Tables)	12 Months Ended
	Dec. 31, 2017
Federal Income Tax Tables
Schedule of deferred tax assets	As of December 31, 2017 2016 Deferred tax assets (liabilities): Net operating losses $ 1,926,842 $ 2,946,115 Unamortized R&D expenses 323,540 689,178 Unamortized startup costs 1,276,853 1,737,633 Orphan Drug Credit 567,188 431,238 Other, net 64,744 108,104 Total deferred tax assets 4,159,167 5,912,268 Valuation allowance (4,159,167 ) (5,912,268 ) Net deferred tax asset $ - $ -
Statutory federal income tax (benefit) provision rate	For year ended December 31, 2017 2016 Federal tax benefit rate 35.0 % 35.0 % Permanent differences -19.9 % -6.4 % Valuation allowance -15.1 % -28.6 % Effective income tax benefit (provision) rate 0 % 0 %

Background and Basis of Prese20

Background and Basis of Presentation (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
State of incorporation		Delaware
Date of incorporation		Apr. 8, 2017
Common Stock, Shares Issued		104,477,936	71,153,300
Ownership percentage		66.00%
Cash payment		$ 315,000
Investment banker fee		$ 50,000
Common stock, share authorized		950,000,000	950,000,000
Common stock, par value		$ 0.0001	$ 0.0001
Common stock, shares outstanding		104,477,936	71,153,300
Preferred Stock, shares authorized		250,000,000
Short-term senior secured convertible notes issued for cash		$ 2,000,000
AEPP [Member]
Common Stock, Shares Issued		103,536,103
Common stock, par value		$ 0.0001
Common stock, shares outstanding		103,536,103
Preferred Stock, shares authorized		62,138,680
Preferred Stock, par value		$ 0.0001
Share exchange ratio as a result of Merger		20:1
Shares received description		In the Merger, each stockholder of Oncolix/DE received 20 shares of a substantially identical class of AEPP stock (Common or Series A Preferred, each with a par value of $0.0001) in exchange for each share of Oncolix/DE (par value $0.001).
AEPP [Member] | Oncolix [Member]
Common Stock, Shares Issued		71,778,700
Common stock purchase price	$ 365,000

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Manufacturing costs			$ 58,153	$ 305,098
Deferred compensation			1,268,013	1,268,013
Rent expense			$ 42,149	$ 42,083
Lease rental obligation	$ 10,248	$ 40,680
Laboratory Equipment [Member]
Property Plant And Equipment Estimated Useful Lives			5 years
Office Furniture Equipment [Member]
Property Plant And Equipment Estimated Useful Lives			3 years

Capital Stock, Options and Wa22

Capital Stock, Options and Warrants (Details) - Options and Warrants - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Common Shares, beginning	7,200,000	7,820,000
Number of Common Shares, Granted	900,000
Number of Common Shares, Exercises	(200,000)	(20,000)
Number of Common Shares, Forfeitures	(200,000)	(600,000)
Number of Common Shares, ending	7,700,000	7,200,000
Vested at December 31, 2017	7,100,000
Weighted Average Exercise Price Per Share, beginning	$ 0.0095	$ 0.0100
Weighted Average Exercise Price Per Share, Grants	0.0900
Weighted Average Exercise Price Per Share, Exercises	0.0050	0.0500
Weighted Average Exercise Price Per Share, Forfeitures	0.0050	0.0150
Weighted Average Exercise Price Per Share, ending	0.0190	$ 0.0095
Vested at December 31, 2017	$ 0.0130
Weighted Average Remaining Life (Years), beginning	4 years 4 months 24 days	5 years 9 months 3 days
Weighted Average Remaining Life (Years), ending	3 years 7 months 21 days	4 years 4 months 24 days
Vested at December 31, 2017	3 years 6 months 10 days

Capital Stock, Options and Wa23

Capital Stock, Options and Warrants (Details Narrative) - USD ($)	Apr. 08, 2017	Aug. 31, 2009	Dec. 31, 2017	Dec. 31, 2016	Aug. 31, 2017	Jul. 31, 2017	Jan. 31, 2015	Aug. 30, 2011	Jan. 24, 2007
Common Stock, Par Value			$ 0.0001	$ 0.0001
Common Stock, Shares Authorized			950,000,000	950,000,000
Common Stock, Shares Issued			104,477,936	71,153,300
Common Stock, Shares Outstanding			104,477,936	71,153,300
Preferred Stock, shares authorized			250,000,000
Shares forfeited						200,000
Deferred offering costs				$ 38,687
Warrant issued for services			4,862
Unamortized stock-based compensation expense			9,724
Common stock issued for services, value			$ 39,880
Oncolix, Inc [Member]
Acquisition of AEPP, Shares	31,765,903
Stock Option Plan [Member]
Warrant exercise price			$ 0.0825
Common shares reserved for future issuance			6,800,000
One Option [Member]
Warrant exercise price			$ 0.005
Shares exercised			200,000
Exercisable average price per share			$ 0.01
Stock Option Plan [Member]
Common shares reserved for future issuance			6,800,000	7,200,000
GHC [Member]
Common Stock, Shares Issued									24,000,000
Commitment to Investment for operations									$ 3,000,000
GHC [Member] | Contract Manufacturing [Member]
Common stock issued for services, shares		10,000,000
Common stock issued for services, value		$ 1,500,000
Common stock issued for services, price per share		$ 0.15
Texas Emerging Technology Fund Investment [Member]
Stipulated penalty description			TETF may require us to repay the $3.9 million investment plus eight percent interest per annum, compounded annually, from the date of the investment, essentially as a stipulated damage or penalty, and TETF will retain its shares of Series A Preferred Stock. In the event of a breach of other conditions of the investment or representations and warranties, TETF may seek any remedies it may have in law or equity. We can terminate our obligations to TETF at any time by the repayment of the amount invested plus 8% interest calculated as described above.
August Secured Notes [Member]
Warrant exercise price			$ 0.075
Warrant [Member]
Warrants Issued During Period for shares			3,200,000
Warrant exercise price			$ 0.0825
Common shares reserved for future issuance			49,477,380
Warrant [Member] | August Secured Notes [Member]
Warrant exercise price			$ 0.09
Common shares reserved for future issuance			17,608,280
Series A Preferred Stock [Member]
Preferred Stock, par value			$ 0.001	$ 0.001
Preferred Stock, shares authorized			150,000,000	150,000,000
Preferred Stock, share issued			63,038,284	62,138,680
Preferred Stock, share outstanding			63,038,284	62,138,680
Preferred stock shares issued upon conversion to common stock			66,871,012
Liquidation preference per share			$ 0.075
Liquidation preference shares outstanding			$ 4,727,871
Shares issuable under arrangements			14,000,000
Preferred Stock, Conversion Basis			Each share of Series A Preferred Stock is currently convertible into 1.0608 shares of Common Stock.
Minimum gross proceeds under firm-commitment for conversion			$ 10,000,000
Preferred Stock conversion description			The Series A Preferred Stock will automatically convert upon either the written consent of the holders of the majority of such shares or the closing of a firm-commitment underwritten public offering with gross proceeds of at least $10 million.
Prepayment of future services							$ 450,000
Unearned portion of equity issued			$ 43,090
Warrants expiry dates			The Preferred Warrants expire if not otherwise exercised at various dates commencing on January 16, 2020 and ending May 12, 2022.
Common shares reserved for future issuance			49,477,380
Preferred Stock conversion shares ratio description			Series A Preferred Stock may be converted into Common Stock at any time at the ratio of 1.0608 shares of Common Stock for every share of Series A Preferred Stock.
Common Stock issuable upon conversion			$ 282,089
Series A Preferred Stock [Member] | Maximum [Member]
Conversion price			$ 0.075		$ 0.0545
Series A Preferred Stock [Member] | Minimum [Member]
Conversion price			$ 0.0707		$ 0.075
Series A Preferred Stock [Member] | Warrant [Member]
Unearned portion of equity issued				$ 43,090
Cashless exercise of warrants, Shares				899,604
Warrants Issued During Period for shares				50,810,720
Warrants issued to acquire shares				2,666,700
Warrants exercised				2,333,340
Warrant exercise price				$ 0.0825
Series A Preferred Stock [Member] | Warrant [Member] | August Secured Notes [Member]
Warrants issued to acquire shares				2,333,340
Warrant exercise price				$ 0.0825
Deferred offering costs				$ 38,687
Series A Preferred Stock [Member] | Warrant [Member] | Placement agent [Member]
Warrants issued to acquire shares				2,000,000
Warrant exercise price				$ 0.0825
Warrants expiry dates				The warrant expires if not exercised in January 2020 and has cashless exercise provisions.
Common Stock
Common Stock, Par Value								$ 0.15
Shares issuable under arrangements			55,872,837					333,340
Cost of services percentage								10.00%
Prepayment of future services								$ 50,000
Unearned portion of equity issued			$ 150,000	$ 269,999
Additional services			$ 1,050,000
Warrants Issued During Period for shares			65,560,120	0
Warrant exercise price			$ 0.09	$ 0.0825
Common shares reserved for future issuance			65,560,121	0
Common Stock | Senior Notes [Member]
Common shares reserved for future issuance			373,083,905
Additional common stock shares issued			76,889,231
Common Stock | GHC [Member] | Contract Manufacturing [Member]
Prepayment of future services				$ 120,688
Common Stock | Warrant [Member]
Warrants Issued During Period for shares			900,000
Warrant exercise price			$ 0.09
Warrants expiry dates			The warrant expires if unexercised on November 30, 2022, and will also expire if the director’s term is terminated.
Volatility rate			40.00%
Common Stock | Warrant [Member] | Placement agent [Member]
Warrant exercise price			$ 0.09
Warrants expiry dates			The August Warrants, expire if not otherwise exercised in or prior to August 3, 2022,
Common Stock | Warrant 4 [Member]
Warrants Issued During Period for shares			17,608,280
Common Stock | Warrant 3 [Member]
Warrants Issued During Period for shares			900,000
Common Stock | Warrant 2 [Member]
Warrants Issued During Period for shares			5,587,284
Common Stock | Warrant 1 [Member]
Warrants Issued During Period for shares			59,072,837

Loss Per Common Share (Details)

Loss Per Common Share (Details) - shares	Dec. 31, 2017	Dec. 31, 2016
Common-Equivalent Shares	268,605,969	120,148,880
Series A Preferred Stock outstanding, Common equivalent [Member]
Common-Equivalent Shares	66,871,012	62,138,160
Warrants to acquire Series A Preferred Stock, Common equivalent [Member]
Common-Equivalent Shares	52,485,605	50,810,720
Options to acquire Common Stock [Member]
Common-Equivalent Shares	6,800,000	7,200,000
Warrants to acquire Common Stock [Member]
Common-Equivalent Shares	65,560,121
Shares issuable upon conversion of notes [Member]
Common-Equivalent Shares	76,889,231

Notes Payable (Details)

Notes Payable (Details)	Dec. 31, 2017USD ($)
Notes Payable Details
Principal due at maturity, including 10% bonus	$ 4,609,509
Unamortized issue costs and discount	(3,782,239)
Carrying amount in the accompanying Balance Sheet	$ 827,270

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended					12 Months Ended
	Aug. 31, 2017	Jun. 30, 2017	May 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Aug. 03, 2017
Accretion of interest						$ 1,579,807	$ 50,749
Units issued conversion of 2016 notes
Payment of secured notes	$ (120,000)					$ (120,000)
Common Stock [Member]
Acquisition of AEPP, Shares						31,765,903
Units issued conversion of 2016 notes
Warrant [Member]
Warrant exercise price						$ 0.0825
Shares reserved for future issuance upon exercise of warrants						49,477,380
Series A Preferred Stock [Member]
Shares reserved for future issuance upon exercise of warrants						49,477,380
Series A Preferred Stock [Member] | Warrant [Member]
Warrants exercised							2,333,340
Warrants issued to acquire preferred shares							2,666,700
Warrant exercise price					$ 0.0825		$ 0.0825
2016 Secured Notes [Member]
Units sold of secured note payable							10.00%
Principal amount				$ 100,000	$ 200,000
Maturities Date of notes range start							Mar. 1, 2017
Maturities Date of notes range end							May 31, 2017
Proceeds From Warrant Exercises							$ 41,365
Debt Instrument Description							Upon maturity, if the noteholders were not offered an option to convert the notes into a new equity offering by the Company, the noteholder was also entitled to receive an additional 20% of the principal amount of the 2016 Notes. The discount attributable to the value of the warrants, the 20% premium, and an additional discount related to the fees and expenses of the issuance of the 2016 Notes of $16,000 was accreted as additional interest expense over the life of the notes.
Common Stock price per share					$ 0.075		$ 0.075
Increase in the interest rate				18.00%
Warrant exercise price			$ 0.0825	$ 0.0825
Additional interest expense			$ (11,435)	$ (8,465)
Interest expenses						$ 89,222	$ 55,912
Accretion of interest						77,814	$ 50,749
2016 Secured Notes [Member] | Series A Preferred Stock [Member]
Acquisition of AEPP, Shares			500,000	500,000
Warrants exercised	2,333,340
Warrants issued to acquire preferred shares					2,666,700
Preferred Stock per share					$ 0.0825		$ 0.0825
Warrant exercise date			May 12, 2022	Mar. 14, 2022
Class of warrants or rights issued	899,604
2017 Notes [Member]
Principal amount						$ 1,320,621
Acquisition of AEPP, Shares						1,580,000
Proceeds From Warrant Exercises						$ 389,421
Debt Instrument Description						The maturity of the 2017 Notes was extended to November 2018. At maturity, if we had not offered the noteholders an option to exchange the 2017 Notes for equity securities in an offering with at least $5 million in gross proceeds, each noteholder would also receive an additional payment equal to 20% of the principal of the 2017 Note. The discount attributable to the value of the warrants, the 20% premium, and an additional discount related to the fees and expenses of the issuance of the notes of $197,389 were being accreted as additional interest expense over the life of the notes.
Common Stock price per share						$ 0.0825
Interest expenses						$ 646,208
Accretion of interest						586,810
Units issued conversion of 2016 notes						1,185,000
Fees paid to placement agent						$ 103,500
2017 Notes [Member] | Common Stock [Member]
Acquisition of AEPP, Shares		447,420		177,980		17,608,280
Common Stock price per share						$ 0.075
Cash expenses						$ 93,889
July Secured Notes [Member]
Principal amount						$ 160,000
Common Stock price per share						$ 0.0825
Interest expenses						$ 103,914
Accretion of interest						$ 87,914
Shares reserved for future issuance upon exercise of warrants						3,200,000
August Secured Notes [Member]
Principal amount						$ 4,190,463
Warrant exercise price						$ 0.075
Interest expenses						$ 1,001,872
Accretion of interest						827,270
Aggregated purchase price						3,561,894
Debt outstanding balance								$ 1,561,894
Cash proceeds						2,000,000
Value of warrants issued						$ 1,194,934
Term of warrant						5 years
Cash offering cost						$ 277,289
Interest rate						10.00%
Description for payment of interest						The August Notes bear interest at a rate of 10% per annum, payable quarterly on November 1, 2017, February 1, 2018, and May 1, 2018 and thereafter, on a monthly basis until maturity. The interest is payable in cash or, at the option of the Company, subject to compliance with certain strict volume and price conditions, in fully tradable Common Stock at a 25% discount to the average of the five lowest closing bid prices for the 20 trading days prior to the interest payment date
Description for redemption of notes						The final maturity of the August Notes is November 1, 2018, but commencing on May 1, 2018 and on the first day of each month thereafter until maturity, we are required to redeem an amount of the 2017 Notes equal to 1/7th of the original principal amount, plus 10% of such monthly redemption amount as a bonus
Description for principal payment of notes						The principal payments shall be made in cash or, subject to the satisfaction of with certain strict volume and price conditions, in Common Stock valued at a 25% discount to the average of the five lowest closing bid prices for the 20 trading days prior to the amortization date
Terms of conversion feature						The August Notes are convertible at the option of the holders at a conversion price equal to $0.0545 per share.
Mandatory conversion, description						In the event of a closing of an $8 million financing in connection with a change in listing of the Common Stock to Nasdaq or the NYSE, the August Notes shall be subject to mandatory conversion into Common Stock at a 30% discount to the offering price. We are required to offer to prepay in cash the aggregate principal amount of the August Notes at 120% of the principal amount thereof plus any unpaid accrued interest to the date of repayment
Amount of financing facility closed						$ 8,000,000
Closing market price						$ 0.109
Beneficial conversion feature						$ 1,822,000
Offering cost						$ 544,711
Percentage of bonus due at maturity						10.00%
Shares underlying Notes and Warrants not registered for resale						95,139,042
Convertible Notes verbally damages agreements Description						As of December 31, 2017, such amount claimed by the holders equals 18% of the related Notes, or $522,349, and accrued interest at 24% per annum of $6,068.
August Secured Notes [Member] | Warrant [Member]
Common Stock price per share						$ 0.0825
Warrant exercise price						$ 0.09
Shares reserved for future issuance upon exercise of warrants						17,608,280
Class of warrants or rights issued						55,872,837
August Secured Notes [Member] | Warrant [Member] | Placement agent [Member]
Warrant exercise price						$ 0.09
Shares reserved for future issuance upon exercise of warrants						5,587,284
Value of warrants issued						$ 267,422
Term of warrant						5 years
Cash offering cost						$ 164,800
Share price						$ 0.109
Volatility rate, description						Because of the limited trading history of Oncolix Common Stock, we continue to use 40% as an estimate of volatility rather than use the historical trading activity of the pre-merger AEPP.
August Secured Notes [Member] | Series A Preferred Stock [Member] | Warrant [Member]
Warrants issued to acquire preferred shares							2,333,340
Warrant exercise price					$ 0.0825		$ 0.0825

Federal Income Tax (Details)

Federal Income Tax (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets (liabilities):
Net operating losses	$ 1,926,842	$ 2,946,115
Unamortized R&D expenses	323,540	689,178
Unamortized startup costs	1,276,853	1,737,633
Orphan Drug Credit	567,188	431,238
Other, net	64,744	108,104
Total deferred tax assets	4,159,167	5,912,268
Valuation allowance	(4,159,167)	(5,912,268)
Net deferred tax asset

Federal Income Tax (Details 1)

Federal Income Tax (Details 1)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Federal tax benefit rate	35.00%	35.00%
Permanent differences	(19.90%)	(6.40%)
Valuation allowance	(15.10%)	(28.60%)
Effective income tax benefit (provision) rate	0.00%	0.00%

Federal Income Tax (Details Nar

Federal Income Tax (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Net operating loss carryforwards	$ 9,200,000
Orphan drug tax credit	$ 567,188	$ 431,238
Description for operating loss carryforwards expiration period	These carryforwards begin to expire in 2027, if not utilized
Change in deferred tax assets	$ (2,800,000)
Change in valuation allowance	$ (1,753,000)
Federal income tax rate	35.00%	35.00%
Tax Cuts and Jobs Act Description	Reduced the federal tax rate for US corporations from 35% to 21% commencing in 2018

Related-Party Transactions (Det

Related-Party Transactions (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accounts payable to Greenville Health System and affiliates	$ 61,935	$ 61,935
Ownership interest held by an affiliate of GHS	40.00%
GHS [Member]
Accounts payable to Greenville Health System and affiliates	$ 61,935	$ 61,935

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)
Licenses [Member]
Royalty fees description	We licensed certain manufacturing technology for the production of Prolanta. We continue to evaluate processes and methods of manufacturing, but if we utilize this licensed technology we must pay a royalty of up to 2% of future sales
Engagement of placement agent [Member]
Exercise of warrants received	4.00%
August Notes [Member]
Description for damage claims on convertible debt	As of December 31, 2017, such amount claimed by to the holders equals 18% of the related August Notes, or $522,349, and accrued interest at 24% per annum of $6,068. Interest would continue to accrue until paid
Accrued damages on convertible debt, amount	$ 522,349
Accrued damages on convertible debt, accrued interest	$ 6,068